Enanta Pharma (ENTA) Tops Q1 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
February 8, 2016 4:02 PM ESTConference Call and Webcast Today at 4:30 p.m. ET
Royalty revenue for paritaprevir containing regimens was $17.9 million $30 million milestone payment received from AbbVie for reimbursement approval in Japan for VIEKIRAX® Cash and marketable securities totaled $236.6 million at December 31, 2015WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first... More
